Results 1 to 10 of about 2,075,366 (204)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). [PDF]

Glob Heart, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment. The availability of new disease-modifying therapies has made successful treatment a reality. Transthyretin amyloid cardiomyopathy can be either age-related (wild-type form) or caused by mutations in the ...
Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ.   +18 more
europepmc   +19 more sources

Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. [PDF]

ESC Heart Fail
AbstractAimsPatients with transthyretin amyloid cardiomyopathy (ATTR‐CM) often experience delayed diagnosis, which may detrimentally impact clinical outcomes. This study aimed to assess the frequency of use of planar scintigraphy with and without single‐photon emission computed tomography (SPECT) in patients with hypertrophic cardiomyopathy (HCM ...
Garcia-Pavia P, Del Moral FJH, Cappelli F, Piriou N, Barriales-Villa R, Munteanu C, Bahus C, Keohane D, Mallaina P, Itti E, Damy T, Elliott P.   +11 more
europepmc   +4 more sources

Navigating the emerging landscape of asymptomatic ATTR-CM: challenges, opportunities and the path ahead. [PDF]

Future Cardiol
Transthyretin amyloid cardiomyopathy (ATTR-CM) has long been considered a rare and inexorably fatal condition. However, advances in noninvasive diagnosis, disease awareness, and available treatments have enabled diagnosis in asymptomatic stages, before development of clinical heart failure (HF). The emerging entity of asymptomatic ATTR-CM presents both
Porcari A.
europepmc   +4 more sources

Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary. [PDF]

Future Cardiol
Plain Language Summary What is this summary about? This summary describes results from a real-world study called the Transthyretin Amyloidosis Outcomes Survey (THAOS for short).
Garcia-Pavia P, Kristen AV, Drachman B, Carlsson M, Amass L, Maurer MS, THAOS investigators.   +6 more
europepmc   +5 more sources

The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. [PDF]

Eur J Heart Fail
Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR‐CM) score, was not externally validated.
Bonfioli GB, Tomasoni D, Vergaro G, Castiglione V, Adamo M, Fabiani I, Loghin V, Lombardi CM, Nicolai A, Metra M, Emdin M, Aimo A.   +11 more
europepmc   +5 more sources

Best Practices in Nuclear Imaging for the Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in KSA: The Eagle Eyes of Local Experts [PDF]

Diagnostics
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a complex and serious form of heart failure caused by the accumulation of transthyretin amyloid protein in the heart muscle. Variable symptoms of ATTR-CM can lead to a delayed diagnosis.
Abdullah Alqarni, Ahmed Aljizeeri, Aquib Mohammadidrees Bakhsh, Hossam Ahmed Maher El-Zeftawy, Hussein R. Farghaly, Mukhtar Ahmed M. Alqadhi, Mushref Algarni, Zain Mohammed Asiri, Ahmed Osman, Haya Haddadin, Islam Alayary, Mouaz H. Al-Mallah   +11 more
doaj   +3 more sources

Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction. [PDF]

J Clin Med
Background: The early detection of transthyretin cardiac amyloidosis (ATTR-CM) is essential, with Tc-99m pyrophosphate scintigraphy (PYP scan) being a key diagnostic tool. Although a previously validated score has shown promise in predicting PYP scan positivity among patients with HFpEF, further evaluation in diverse cohorts is necessary.
Chedid El Helou M, Gupta M, Hussain M, Hanna M, Blumer V, William P, Desai MY, Abadie BQ, Ives L, Tang WHW, Jaber WA, Collier P, Martyn T.   +12 more
europepmc   +4 more sources

Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review [PDF]

Journal of Comparative Effectiveness Research
Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are ...
Jose Nativi-Nicolau, Ali Yilmaz, Noel Dasgupta, Richard Macey, James Cochrane, Judith Peatman, Catherine Summers, Jennifer Luth, Ronald Zolty   +8 more
doaj   +3 more sources

Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience [PDF]

Frontiers in Cardiovascular Medicine, 2023
AimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy. Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT).
Yousuf Razvi, Aldostefano Porcari, Aldostefano Porcari, Concetta Di Nora, Rishi K. Patel, Adam Ioannou, Muhammad U. Rauf, Ambra Masi, Steven Law, Liza Chacko, Tamer Rezk, Sriram Ravichandran, Janet Gilbertson, Dorota Rowczenio, Iona J. Blakeney, Nandita Kaza, David F. Hutt, Helen Lachmann, Ashutosh Wechalekar, William Moody, Sern Lim, Colin Chue, Carol Whelan, Lucia Venneri, Ana Martinez-Naharro, Marco Merlo, Gianfranco Sinagra, Ugolino Livi, Philip Hawkins, Marianna Fontana, Julian D. Gillmore   +30 more
doaj   +4 more sources

Improving Long-Term Outcomes in ATTR-CM: Aiming at a Moving Target. [PDF]

JACC CardioOncol
[Figure: see text]
Fine NM.
europepmc   +4 more sources